PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Exp Neurol. Author manuscript; available in PMC 2012 June 1.
Published in final edited form as:
PMCID: PMC3100418
NIHMSID: NIHMS274861

Prolonged cannabinoid exposure alters GABAA receptor mediated synaptic function in cultured hippocampal neurons

Abstract

Developing cannabinoid based medication along with marijuana’s recreational use makes it important to investigate molecular adaptations the endocannabinoid system undergoes following prolonged use and withdrawal. Repeated cannabinoid administration results in development of tolerance and produces withdrawal symptoms that may include seizures. Here we employed electrophysiological and immunochemical techniques to investigate the effects of prolonged CB1 receptor agonist exposure on cultured hippocampal neurons. Approximately 60% of CB1 receptors colocalize to GABAergic terminals in hippocampal cultures. Prolonged treatment with the cannabinamimetic WIN 55,212-2 (+WIN, 1μM, 24-h) caused profound CB1 receptor downregulation accompanied by neuronal hyperexcitability. Furthermore, prolonged +WIN treatment resulted in increased GABA release as indicated by increased mIPSC frequency, a diminished GABAergic inhibition as indicated by reduction in mIPSC amplitude and a reduction in GABAA channel number. Additionally, surface staining for the GABAA β2/3 receptor subunits was decreased, while no changes in staining for the presynaptic vesicular GABA transporter were observed, indicating that GABAergic terminals remained intact. These findings demonstrate that agonist-induced downregulation of the CB1 receptor in hippocampal cultures results in neuronal hyperexcitability that may be attributed, in part, to alterations in both presynaptic GABA release mechanisms and postsynaptic GABAA receptor function demonstrating a novel role for cannabinoid-dependent presynaptic control of neuronal transmission.

Keywords: cannabinoid withdrawal, hyperexcitability, GABAA, CB1, receptor downregulation, WIN 55212-2

Introduction

Cannabinoid type 1 (CB1) receptors play a critical role in modulating neuronal excitability and synaptic plasticity (Deshpande, et al., 2007, Monory, et al., 2006, Wallace, et al., 2003). The Gi/o coupled CB1 receptor is the most abundant G-protein coupled receptor in the central nervous system, localized at both inhibitory and excitatory terminals and regulates a multitude of neurophysiological processes owing to its widespread expression throughout the brain with particularly high expression in the hippocampus (Tsou, et al., 1998). Studies have shown that postsynaptic neuronal depolarization results in “on demand” synthesis and release of endocannabinoids that activates presynaptic CB1 receptors in a retrograde fashion and modulate neurotransmitter release [reviewed in: (Kano, et al., 2009)]. Dependent on what class of terminals the CB1 receptor is present, this regulatory mechanism is termed depolarization-induced suppression of inhibition (DSI- when GABA is involved) or excitation (DSE- when glutamate is involved) (Katona and Freund, 2008). Thus, the CB1 receptor plays an important role in regulation of both inhibitory and excitatory synaptic transmission and has become an attractive therapeutic target in various pathophysiological conditions including seizures. Previous studies have demonstrated increased endocannabinoid release following seizures (Wallace, et al., 2003), CB1 receptor dependent anticonvulsant activity (Blair, et al., 2006, Deshpande, et al., 2007, Wallace, et al., 2002, Wallace, et al., 2001) and pro-convulsant effects following CB1 receptor antagonism (Deshpande, et al., 2007, Wallace, et al., 2003) in models of epilepsy.

There is a growing interest in targeting components of the endocannabinoid system for potential therapeutic use (Blair, et al., 2009, Howlett, et al., 2002, Mackie, 2006), which along with marijuana’s recreational use makes it important to identify molecular adaptations this system undergoes following prolonged use and withdrawal. Repeated exposure to CB1 agonists results in the development of tolerance to their predominantly inhibitory physiological effects [reviewed in: (Abood and Martin, 1992)] and upon withdrawal, irritability, restlessness, anxiety (Hasin, et al., 2008) and in some cases seizures (Wade, et al., 2006) have been observed. Recently, we reported that prolonged exposure of epileptic neuronal cultures to varying concentrations (10-1000 nM) of the CB1 receptor agonist WIN 55212-2 produced tolerance to its anticonvulsant effect as indicated by a concentration-dependent increase in epileptiform seizure discharge frequency and decrease/downregulation of CB1 receptor expression (Blair, et al., 2009). However, mechanisms underlying the increase in neuronal excitability following CB1 receptor downregulation are not fully understood.

To address this issue, we pharmacologically-induced CB1 receptor downregulation in hippocampal neuronal cultures and employed electrophysiological and immunochemical techniques to investigate its effects on GABAergic synaptic transmission. Previous findings from our laboratory demonstrate that in our hippocampal neuronal culture preparation, a large percentage (≈ 60%) of the CB1 receptor colocalizes at VGAT+ (GABAergic) terminals, almost twice that (≈ 36%) colocalized at VGLUT1+ (glutamatergic) terminals (Blair, et al., 2009). Thus, we chose to initially evaluate GABAergic synaptic function following pharmacologically-induced CB1 receptor downregulation in hippocampal neuronal cultures. This model provides an ideal preparation to study these synaptic events in a controlled environment. Our results indicate that immediately following withdrawal of the cannabimimetic WIN 55,212-2 (+WIN) after a prolonged exposure (24-h), a massive neuronal hyperexcitability ensues. Additionally, CB1 receptor downregulation was accompanied by an increased GABA release from presynaptic terminals as indicated by increased frequency for miniature inhibitory post synaptic current events (mIPSC). Furthermore, we observed a diminished GABAergic synaptic inhibition as indicated by a reduction in mIPSC amplitude and also a reduction in GABAA channel number without an effect on number of GABAergic synapses. This study demonstrates that the neuronal hyperexcitability observed following agonist-induced downregulation of the CB1 receptor may result from alterations in both presynaptic GABA release and postsynaptic GABAA receptor function thus demonstrating a novel role of cannabinoid-dependent presynaptic control of neuronal transmission.

Materials and methods

All the drugs and reagents were purchased from Sigma Chemical Co (St. Louis, MO) unless otherwise noted. Sodium pyruvate, minimum essential media containing Earle’s salts (MEM), fetal bovine serum and horse serum were obtained from Gibco-BRL (Invitrogen Corp., Carlsbad, CA). Stocks (1 mM) of S(−)-[2,3-Dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (−WIN) and R(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2, 3-de]1,4-benzoxa zinyl]-(1-naphthalenyl methanone mesylate (+WIN) were made up in dimethyl sulfoxide (DMSO) that were then diluted at a minimum of 1:1000 to a final working concentration in the physiological bath recording solution (pBRS; see composition below).

Hippocampal neuronal cultures

All animal use procedures were in strict accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and approved by Virginia Commonwealth University’s Institutional Animal Care and Use Committee. Studies were conducted on primary mixed hippocampal neuronal cultures prepared as described previously with slight modifications (Blair, et al., 2009). Briefly, hippocampal cells were prepared from 2-day postnatal Sprague–Dawley rats (Harlan, Frederick, MD) and plated at a density of 2.0 ×104 cells/cm2 onto a glial support layer previously plated onto poly-L-lysine (0.05 mg/ml) coated Lab-Tek two-well cover glass chambers or 35 mm cell culture dishes (Nunc, Naperville, IL). Cultures were maintained at 37°C in a 5% CO2/95% air atmosphere and fed twice weekly with MEM enriched with N3 supplement containing 25 mM HEPES buffer (pH 7.4), 2 mM L-glutamine, 3 mM glucose, 100 mg/ml transferrin, 5 mg/ml insulin, 100 mM putrescine, 3 nM sodium selenite, 200 nM progesterone, 1 mM sodium pyruvate, 0.1% ovalbumin, 0.2 ng/ml triiodothyroxine, 0.4 ng/ml corticosterone and supplemented with a glial bed-condition media (20%).

Experimental protocol for cannabinoid treatment

Hippocampal neuronal cultures (DIV 14-16) were exposed to either the active enantiomer (+WIN, 1 μM) or inactive enantiomer (−WIN, 1 μM) or vehicle control (0.01% DMSO) in the maintenance medium for 24-h. At the end of this period, culture plates were washed with pBRS and immediately utilized for electrophysiology or immunocytochemistry experiments described below. Thus, WIN treatment refers to a prolonged (24-h) exposure to cannabinamimetic (1 μM) and its subsequent removal (withdrawal). WIN was not present in the recording medium when experiments were conducted.

Electrophysiology

Whole cell current clamp recordings were performed using previously established procedures (Blair, et al., 2009). Briefly, a cell culture dish was mounted on the stage of an inverted microscope (Nikon Diaphot, Tokyo, Japan) continuously perfused (1 ml/min) with pBRS containing (in mM): 145 NaCl, 2.5 KCl, 10 HEPES, 2 CaCl2, 10 glucose, and 0.002 glycine, pH adjusted to 7.3 with NaOH, and osmolarity adjusted to 325 ± 5 mOsm with sucrose. Patch electrodes were pulled on a Brown-Flaming P-80C electrode puller (Sutter Instruments, Novato, CA), fire-polished and had a resistance of 3 to 5 MΩ when filled with a solution containing (in mM): 140 K+ gluconate, 1.1 EGTA, 1 MgCl2, and 10 Na-HEPES, pH 7.2, osmolarity adjusted to 290 ± 10 mOsm with sucrose. Neurons were recorded for up to 60 min.

Whole-cell voltage clamp configuration was employed to obtain mIPSCs. Patch electrodes were filled with an internal solution containing (in mM): 153.3 CsCl, 1.0 MgCl2, 10.0 HEPES, 5.0 EGTA, with a pH of 7.30 (with sterile filtered CsOH) and osmolarity of 280-295 mOsm. The external solution composition was the same as described above in the current-clamp section. For mIPSC recordings, glutamate receptor-mediated synaptic currents were blocked by adding 50 μM D(−)-2-amino-5-phosphonovaleric acid (D-APV) and 20 μM 6,7-dinitroquinoaxaline-2,3-dione (DNQX) to the external solution. Action potentials were blocked by adding 1 μM tetrodotoxin (TTX) to the external solution. Voltage-clamp recordings were performed at a holding potential of −60 mV. Five-minute epochs of synaptic activity were recorded. Recording was terminated if the series resistance exceeded 20 MΩ. Signals were amplified using a Multiclamp 700B amplifier (Molecular Devices, Foster City, CA), low-pass filtered at 2 kHz, sampled at 10 kHz and recorded for off-line analysis using the Pclamp software (ver 10) using a Digidata 1440A (Molecular Devices, Foster City, CA).

Analyses of mIPSC

Off-line analyses of mIPSC were performed using MiniAnalysis software ver 6.0.7 (Synaptosoft, Decatur, GA). Offline sorting of the mIPSCs for further analysis used the following criteria: 1) the threshold for mIPSC detection was set at three times the root mean square of baseline noise, 2) to minimize the analysis of events that are dendritically filtered, all mIPSCs analyzed had a rise time of < 2 ms and half-width > 4 ms, 3) to attempt to minimize cases of inadequate space clamp, neurons in which series resistance increased >20% were discarded (Brünig, et al., 2001, Goodkin, et al., 2005, Rajasekaran, et al., 2007). In addition, event amplitudes were plotted against rise times and examined for a possible correlation. A significant correlation (r2 > 0.5) was assumed to signify inadequate space clamp and neurons in which this occurred (<0.2%) were discarded (Cohen, et al., 2000). The accuracy of detection was visually confirmed. The amplitude of all mIPSCs greater than the detection criteria was included in the amplitude analysis. Because the distribution of mIPSC amplitude is skewed, median mIPSC amplitude was calculated for each neuron, and the mean of the medians is reported (Edwards, et al., 1990). The 10-90% rise time, the time interval between the last data point with a value of 10% and the first data point with a value of 90% of the peak amplitude, was determined for all selected events during the recording period. The decay phase was calculated by fitting individual mIPSCs with a 10-90% rise time <2 ms to a two-exponential function characterized by two time constants (τ1 and τ2) and accepted if r2 > 0.70 (Goodkin, et al., 2005). For each neuron, the decay phase was based on at least 25 current traces selected randomly that met these criterions. Weighted decay (τw) was calculated using the formula:

equation M1

where τ1 and τ2 represent the fast and slow decay times and A1 and A2 represent the amplitude of the fast and slow components, respectively. Decay phase, 10-90% rise time, and frequency values are reported as mean ± SEM. Frequencies were compared between groups using the nonparametric Kolmogorov–Smirnov (K-S) test, and mIPSC amplitudes and their kinetics were compared with an unpaired t-test.

Peak scaled nonstationary noise analysis (NSNA) of mIPSCs (De Koninck and Mody, 1994, Otis, et al., 1994, Traynelis, et al., 1993) was conducted using the Mini analysis software functionality by averaging 50 events to form a single mean ensemble mIPSC time course for a given neuron. The ensemble average was scaled up or down to the size of each original trace and then subtracted. Subtraction of the average ensemble current left a noise trace which fluctuated around the zero current level. The variance (σ2) of the current was calculated for 20 amplitude bins. Then the values of σ2 were plotted against the mean current (I) and data plotted in this manner were fitted by a parabolic curve with the equation:

equation M2

where i is the unitary current and N is the number of open channels activated during the mIPSC. The single-channel conductance (γ) was derived by dividing i by the driving force for GABAA-mediated currents, determined from the Goldman-Hodgkin-Katz equation to be −60 mV (Eholding–EGABA) in our solutions. The basal recording noise was subtracted prior to conducting NSNA (Cohen, et al., 2000, Hartman, et al., 2006, Kilman, et al., 2002).

Immunocytochemistry

Hippocampal cultures treated with WIN (1 μM, 24 h, followed by washout) were evaluated immunocytochemically for CB1 receptor staining in association with staining for either the vesicular GABA transporter (VGAT) marker for inhibitory terminals or the GABAA2/3 receptor subunit using previously established procedures (Blair, et al., 2009, Blair, et al., 2004). Colocalization analysis for the CB1 receptor at VGAT positive inhibitory terminals was carried out using a rabbit antiserum to the C-terminal tail of CB1 (generous gift of Dr. Maurice Elphick) (Egertová and Elphick, 2000) followed by staining with rabbit antiserum to the vesicular GABA transporter (VGAT: 2 μg/ml in SBBT, 16h 4°C; Millipore, Billerica, MA). Staining with the two rabbit primary antibodies was carried out using conditions to block any false host species cross-reactivity utilizing methodology previously published from our laboratory (Blair, et al., 2009). Briefly, fixed cultures (4% PF, 10 min) were blocked and permeabilized in SuperBlock® blocking buffer (Pierce, Rockford IL) containing 0.2% Triton X-100 for 60 min at room temperature, followed by a 3 h incubation with rabbit antiserum to the C-terminal tail of CB1(1:5000) in SuperBlock® blocking buffer containing 0.1% Triton X-100 (SBBT). Labeled cultures were washed and incubated with a monovalent Fab fragment secondary antibody (biotin-SP-AffiniPure Fab fragment goat-anti-rabbit IgG; 1:100 in SBBT, 1h). Following wash, cultures were stained for CB1 with FITC-streptavidin (5 μg/ml in SBBT, 1h). Stained cultures were then incubated in biotin (0.05% in PBST, 1h) to saturate all free sites on the FITC-streptavidin complex. Following wash, CB1 stained cultures were then incubated in the second primary antibody (rabbit anti-VGAT; 2 μg/ml in SBBT, 16h 4°C), washed and incubated in biotin-SP-AffiniPure goat-anti-rabbit IgG (1:100 in SBBT, 1h). Following wash, labeled cultures were incubated in Texas red-streptavidin (5 μg/ml in SBBT, 1h). All biotin conjugated secondary antibodies and streptavidin conjugates were purchased form Jackson Immunoresearch (West Grove, PA). Appropriate no primary antibody controls were carried out to confirm no cross-reactivity between first and second rabbit antisera. For double-immunofluorescent staining of surface CB1 and GABAA receptors, viable neuronal cultures were brought to 4°C in ice-cold pBRS and then incubated with rabbit antisera against the N-terminus CB1 receptor (1:1000; generously donated by Dr. Ken Mackie) (Tsou, et al., 1998) in combination with mouse antisera against the GABAA2/3 receptor subunits (20 μg/ml, clone BD-17; Millipore, Billerica, MA) in Superblock for 90 min at 4°C. Following wash in ice-cold pBRS, labeled cultures were then fixed (4% PF, 10 min), washed in PBS and then incubated with Alexa Fluor® 488 (anti-rabbit) and 594 (anti-mouse) conjugated secondary antibodies (Invitrogen Corp., Carlsbad, CA). All stained cultures were covered with ProLong® Gold antifade reagent (Invitrogen) and cover slipped.

Confocal Microscopy

Immunofluorescent stained cultures were evaluated using a Leica TCS-SP2 confocal laser scanning microscope with a 63X/1.4 n.a. oil objective in sequential scan mode acquisition (Leica Microsystems Inc., Bannockburn, IL). Analysis of CB1 and VGAT colocalization was carried out on 16-bit gray scale confocal scans from each channel using ImageJ (NIH, public domain; colocalization threshold plug-in: authors Tony Collins and Wayne Rasband) to calculate Mander’s colocalization coefficient (above threshold) for each channel (tM1: CB1; tM2: VGAT) and Pearson’s correlation coefficient (above threshold) following automatic image background correction and threshold determination. Intensity analysis of CB1 and GABAA2/3 receptor staining was carried out on eight consecutive 16-bit gray scale confocal z-scans from each field evaluated. Confocal scan images underwent threshold adjustment and were then analyzed for whole field integrated density limited to threshold using ImageJ. Values for integrated density from each field evaluated were averaged from the eight consecutive confocal z-scans and a minimum of three fields per sample were analyzed.

Western blot analysis

Following experimental treatment, hippocampal neuronal cultures were rinsed with ice cold PBS (2 × 2.0 ml wash/35 mm plate) and then scraped into ice cold lysis buffer containing 50 mM Tris-HCL (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% NP-40 and a cocktail of protease inhibitors containing 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), pepstatinA, E-64, bestatin, leupeptin, and aprotinin (Sigma-Aldrich, St. Louis, MO). Three 35 mm neuronal culture plates were pooled into 300 uL of lysis buffer per sample to acquire a sufficient concentration of protein for immunoblot analysis. Samples were vortexed and underwent freeze-thaw prior to resolving on SDS-PAGE. A maximum amount of sample was prepared into LDS sample buffer containing a reducing agent (NuPAGE®, Invitrogen, Carlsbad, CA) and heated at 70°C for 10 minutes. Fifteen microliters of each sample were resolved on a 4-12% Bis-Tris 15-well mini gel (NuPAGE®, Invitrogen). In addition, dual color Precision Plus Protein™ standards (Biorad, Hercules, CA) were used for molecular weight determination. Resolved samples were then transferred onto PVDF membrane using NuPAGE® transfer buffer containing 10% methanol. Following transfer, immunoblots were briefly washed in PBS containing 0.05% Tween-20 (PBST) and blocked overnight in PBST containing 3% blotting-grade blocker (Biorad). Immunoblots were then incubated in PBST with blocker containing either a rabbit antiserum to the C-terminal tail of CB1 (1:1000, 3 hours; generous gift of Dr. Maurice Elphick) (Egertová & Elphick 2000) or a mouse antisera against the GABAA2/3 receptor subunits (2 μg/ml, 16h at 4°C; clone BD-17; Millipore, Billerica, MA). For protein loading control, immunoblots were incubated with mouse antisera against β-Actin (1:4000; clone AC-15, Sigma-Aldrich, St. Loius, MO). Following wash in PBST, immunoblots were incubated with PBST with blocker containing either goat-anti-rabbit-IgG-HRP or goat-anti-mouse-IgG-HRP (1:2000, 1h; Santa Cruz Biotech., Inc., Santa Cruz, CA), washed in PBST and incubated in chemiluminescent substrate (SuperSignal® West Pico; Thermo Scientific, Rockford, IL). Stained immunoblots were exposed to imaging film (Kodak X-OMAT™ Blue XB; Carestream Health Inc., Rochester, NY). Developed films were digitized using a high dynamic range transparency scanner (Epson Expression 1680; Epson U.S., Long Beach, CA). Digitized images were analyzed using ImageJ software to determine integrated density that was within threshold above background for each protein band. Values were normalized against their respective β-Actin integrated densities to correct for protein loading.

Data analysis

Data were analyzed using SigmaStat 2.0 and graphs were generated using SigmaPlot analysis software 11 (Systat Software Inc., San Jose, CA). All data are represented as mean ± SEM. Immunocytochemical intensity analysis is presented as a percent of control. A value of p < 0.05 was considered statistically significant. Image processing for representative figures was carried out with Adobe Photoshop software (CS3, Adobe Systems Inc., San Jose, CA).

Results

Prolonged +WIN treatment causes neuronal hyperexcitability

Neuronal activity in 14-day old cultured hippocampal neurons was assessed using the whole-cell current clamp configuration. Recordings from −WIN (control) treated neurons (1 μM, 24-h, followed by washout) showed occasional spontaneous action potentials (n= 10, Fig. 1A). However, recordings obtained from +WIN treated neurons (1 μM, 24-h, followed by washout) demonstrated high frequency spiking approaching 3 Hz in some neurons (n= 10, Fig. 1B). This continuous spike discharge activity was sustained throughout the recording period. No significant differences in resting membrane potential or input resistance were observed between the −WIN and +WIN treated neurons. −WIN treated neurons exhibited a mean membrane potential of −63.2 ± 2.5 mV and a mean input resistance of 125.8 ± 8.2 MΩ, whereas the +WIN treated neurons demonstrated a mean membrane potential of −61.8 ± 2.1 mV and a mean input resistance of 120.9 ± 9.4 MΩ (n= 7, p> 0.05, t-test). Control untreated neurons displayed electrophysiological characteristics that were not significantly different from −WIN treated neurons (data not shown). Hence data from −WIN treated neurons has been used as a control for comparing effects of prolonged +WIN exposure.

Figure 1
Neuronal hyperexcitability following prolonged +WIN exposure in cultured hippocampal neurons

Prolonged +WIN treatment results in decreased inhibitory synaptic transmission

In order to investigate the effect of +WIN withdrawal on inhibitory synaptic transmission, we recorded mIPSCs from −WIN and +WIN (1 μM, 24-h, followed by washout) treated neurons. Neurons were voltage clamped at −60 mV and mIPSCs were recorded as an inward current (Fig. 2A) in an isotonic chloride environment in the presence of 1 μM TTX, 50 μM D-APV and 20 μM DNQX (see: materials and methods), to isolate miniature inhibitory currents. The presence of these agents also terminated the high frequency spiking observed following prolonged +WIN treatment and the addition of bicuculline (20 μM) fully abolished the miniature currents, confirming that these events were mediated by GABAA receptors (data not shown).

Figure 2
Diminished GABAergic transmission following prolonged +WIN exposure

There were distinct differences between mIPSCs recorded from +WIN treated neurons compared to −WIN control neurons. The +WIN treated neurons had smaller amplitude and higher frequency of mIPSCs compared to −WIN treated neurons (Fig. 2A). The average amplitude of mIPSCs decreased to 40% of −WIN values (Fig. 2B). Because the distribution of individual mIPSC amplitudes tends to be skewed by larger-amplitude mIPSCs, the median value is reported since it is more representative of the distribution (Edwards, et al., 1990). The amplitude distribution histograms depicted a leftward shift towards smaller amplitude values in +WIN treated neurons (Fig. 2C). A population mean of the median values for the −WIN neurons was 66.6 ± 4.6 pA, while that for the +WIN treated neurons was 40.8 ± 3.2 pA (n= 6, p < 0.01, t-test).

In contrast to a decrease in amplitude, prolonged +WIN treatment resulted in a small but significant increase in the frequency of mIPSCs. In +WIN treated neurons, mIPSCs occurred at a frequency of 0.36 ± 0.06 Hz, which was significantly higher than mIPSC frequency in −WIN treated neurons of 0.18 ± 0.05 Hz (n= 10, p< 0.01, K-S test). The cumulative distribution graph for frequency indicates a slight leftward shift towards higher frequency values and decreased inter-event interval following prolonged +WIN treatment (Fig. 2D).

Analyses of mIPSC kinetics

We next compared the decay phases of mIPSCs. Compared to the −WIN treated neurons, the decay phase of mIPSCs was prolonged in +WIN treated neurons. The population means for both +WIN and −WIN groups was obtained by averaging the mean decay constants for each neuron recorded. The population means of mIPSCs decay constants recorded from the −WIN treated neurons were τ1 = 21.77 ± 2.71 and τ2 = 31.13 ± 8.25, and those for the +WIN treated neurons were τ1 = 29.58 ± 5.26 and τ2 = 90.69 ± 10.5. While the faster component τ1 remained unchanged, the τ2 component was significantly delayed in +WIN treated neurons (n= 6, p= 0.02, t-test). In addition, the mean weighted decay (τw) was also significantly slower in +WIN treated neurons (τw = 50.09 ± 3.47) compared to −WIN treated neurons (τw = 26.15 ± 3.88) (n= 5, p <0.01, t-test).

The mean rise time in −WIN treated neuron (4.31 ± 0.17 ms) was not significantly different from the rise time in +WIN treated neuron (4.19 ± 0.24 ms) (n= 6, p= 0.8, t-test). The pooled rise times were binned at 1 ms intervals into three subpopulations: <3 ms, 3−5 ms, and >5 ms. This analysis showed no significant shift in the proportion of events in each subpopulation of rise times for mIPSCs when comparing −WIN and +WIN treated neurons (Fig. 2E).

Charge transfer as represented by area of currents (pA × ms) was then calculated as a measure of mIPSC inhibition. Total charge transfer was significantly smaller in +WIN treated neurons compared to −WIN treated neurons. The mean charge transfer for −WIN and +WIN treated neurons was 1295.15 ± 159.9 pA × ms and 850.97 ± 23.5 pA × ms respectively (n= 5, p= 0.05, t-test).

Taken together, our observation that mIPSC amplitude and charge transfer decreased significantly following +WIN treatment indicates a reduction in GABA mediated synaptic inhibition in these neurons. Additionally, the decreased mIPSC amplitude occurred without significant changes in the rise-times suggesting that the reduced inhibition was not related to loss of GABAergic synapses proximal to soma (also see immunohistochemistry data below).

Non stationary noise analysis indicates that average numbers of GABAA channels but not their single-channel conductance is reduced from prolonged +WIN exposure

The reduction in mIPSC amplitude could be attributable to a decrease in the single-channel conductance (γ) of GABAA receptors or to a reduction in the number of open channels (N) or the open probability of an activated channel (Po). We performed nonstationary noise analysis on the mIPSC currents (De Koninck and Mody, 1994, Otis, et al., 1994, Traynelis, et al., 1993) to distinguish between these possibilities. For each neuron, individual mIPSCs were peak scaled to the average mIPSC amplitude (Fig. 3A and B) to give the mean versus variance curve that were fitted by a parabolic function (Fig. 3C and D, also see materials and methods). The mean single channel conductance (γ) from the +WIN group was 35.96 ±1.5 pS, which was not significantly different from the γ in −WIN treated neurons (39.18 ± 1.6 pS) (n= 5, t-test, Fig. 3E). These findings for mean single channel conductance are in agreement to other previously reported values of 30-40 pS derived from noise analysis and single-channel recordings (Otis, et al., 1994, Traynelis, et al., 1993).

Figure 3
Nonstationary noise analysis suggested a decrease in the number of open GABAA receptor channels per quantum of transmitter released after a prolonged +WIN exposure

The peak amplitude is a function of both single channel conductance γ and number of activated channels NPo. Since γ didn’t decrease in +WIN treated neurons, we surmised that N should be affected. Indeed, the number of activated channels decreased significantly in +WIN treated neurons compared to −WIN treated neurons (N= 19.04 ± 2.25 Vs. N= 34.18 ± 3.51 respectively, n= 6, p< 0.01, t-test, Fig. 3F). These data indicate that the number of activated GABAA channels at the peak of mIPSC amplitude are reduced in +WIN treated neurons. This reduced inhibition could underlie the hyperexcitability observed in these neurons.

Prolonged +WIN exposure results in downregulation of the CB1 receptor at inhibitory GABAergic terminals

To evaluate the effect of +WIN treatment (1 μM, 24-h, followed by washout) on CB1 receptor expression at GABAergic inhibitory terminals, colocalization analysis of hippocampal cultures double-labeled with two rabbit antibodies against the CB1 receptor and the vesicular GABA transporter (VGAT) was carried out using previously published methods to block any false host species cross-reactivity (Blair, et al., 2009). Control hippocampal cultures treated with −WIN showed distinct punctate CB1 receptor staining (green) throughout the processes, some of which also stained positive for VGAT (red) (Fig. 4). Prolonged exposure to +WIN resulted in a dramatic downregulation of CB1 receptor levels, while no effect on VGAT expression was observed (Fig 4). Additionally, intensity analysis of confocal scans revealed no significant change in VGAT expression between −WIN (100 ± 14.2%) and +WIN-treated (110.9 ± 4.5%) cultures (n= 4, p= 0.493, t-test). Overlay images for CB1 (green) and VGAT (red) demonstrate a high degree of colocalization (yellow) in the −WIN treated cultures while a near total loss in colocalization was observed in +WIN treated cultures (Fig 4, bottom panels). Additionally, the presence of exclusive CB1 (green) staining in the overlay image of the −WIN treated cultures (bottom left panel) indicates correct staining conditions for blocking any false host species cross-reactivity between the two rabbit antibodies. Colocalization analysis of confocal scans of double antibody stains from −WIN treated cultures indicate that staining for CB1 receptor and VGAT colocalize on inhibitory terminals with a Pearson’s correlation coefficient of 0.825±0.019 and Mander’s overlap coefficients of tM1= 0.576 ± 0.067 and tM2= 0.484 ± 0.031 for CB1 and VGAT respectively (n= 4). This is in agreement with previous findings of CB1/VGAT colocalization in this culture preparation (Blair, et al., 2009). Analysis of confocal scans of double antibody stains from +WIN treated cultures indicated the absence of colocalization between CB1 and VGAT. Thus, prolonged exposure of hippocampal neuronal cultures to +WIN results in a dramatic downregulation of CB1 receptor expression on neuronal processes of which approximately 60% (tM1 = 0.576 ± 0.067) are VGAT-positive inhibitory terminals.

Figure 4
Loss of CB1 receptor expression at GABAergic (VGAT +) terminals after a prolonged +WIN exposure

Prolonged +WIN exposure decreases both CB1 and GABAA receptor surface expression

To evaluate the effect that prolonged +WIN treatment (1 μM, 24-h, followed by washout) has on surface expression for both CB1 and GABAA receptors, immunocytochemical analysis was carried out by double-labeling live cells at 4° C with antibodies against the N-terminus of CB1 and the extracellular chain of the GABAA β2/3 receptor subunits. Following extensive washing in ice-cold pBRS, labeled cells were then fixed, stained immunofluorescently and analyzed by confocal microscopy. Surface CB1 receptor expression in −WIN treated hippocampal cultures demonstrated punctate staining (green) throughout the neuronal processes (Fig. 5A, top-left). Following prolonged treatment with +WIN, a dramatic loss of surface CB1 receptor staining was observed and was comparable to the loss of total cell receptor staining seen using the C-terminus specific antibody (Fig. 5A, top-right). Intensity analysis of surface CB1 receptor staining revealed a significant decrease in +WIN treated cultures of 87.7 ± 1.52% (p< 0.001, n= 6) in integrated density when compared to −WIN treated cultures (Fig. 5B).

Figure 5
Decrease in surface GABAA2/3 receptor subunit and CB1 receptor expression following prolonged +WIN exposure

Surface GABAA β2/3 receptor subunit staining was utilized as an indicator for overall surface levels of the GABAA receptor since the majority of hippocampal receptors contain at least one of these two β isotypes (Wisden, et al., 1992). In −WIN treated hippocampal cultures, staining for the GABAA β2/3 receptor subunits (red) was demonstrated as intense staining across the cell membrane visualized as distinct punctate staining representative of clusters of GABAA receptors containing the β2/3 subunits (Fig. 5A, bottom-left) in agreement with previous findings in this culture preparation (Blair, et al., 2004). Following exposure to +WIN, a decrease in staining intensity for the GABAA β2/3 receptor subunits was observed (Fig. 5A, bottom-right). Intensity analysis of surface GABAA β2/3 receptor subunit staining revealed a significant decrease in +WIN treated cultures of 25.0 ± 6.86% (p ≤ 0.04, n= 6) in integrated density when compared to −WIN treated cultures (Fig. 5C).

To further analyze the effect that prolonged +WIN exposure to hippocampal neuronal cultures has on levels of both CB1 and GABAA receptor protein levels, quantitative immunoblot analysis of total cellular lysates from −WIN control and +WIN treated neuronal cultures was carried out. CB1 receptor staining of immunoblots of hippocampal neuronal culture total cell lysates revealed a prominent band with a molecular mass of ≈45 kDa in the −WIN control group (Fig. 6A, lane 1). These findings are in agreement with a previous study characterizing the antibody directed to the C-terminal tail of the CB1 receptor used in the present study (Egertová & Elphick 2000). Prolonged exposure to +WIN resulted in a total loss of CB1 receptor staining (Fig. 6A, lane 2). Quantitative analysis revealed that prolonged +WIN exposure resulted in a significant and total loss in staining for the CB1 receptor when compared to −WIN controls (100 ± 24.6%) (p ≤ 0.01, n= 3, Fig. 6B).

Figure 6
Western blot analyses of total cell lysates from hippocampal neuronal cultures following prolonged exposure to either −WIN control (lane 1) or +WIN (lane 2) using antibodies against CB1 and the GABAA2/3 receptor subunits

In −WIN control treated neuronal cultures, immunoblot analysis of total cellular lysates for GABAA β2/3 receptor subunit revealed a single protein band with a molecular mass of ≈55 kDa (Fig. 6C, lane 1). Prolonged exposure to +WIN resulted in an observed decrease in staining for the GABAA β2/3 receptor subunit (Fig. 6C, lane 2) which reflected a significant reduction of 40.8 ± 8.6% (p ≤ 0.04, n= 3, −WIN; n=5, +WIN) from −WIN treated controls (100 ± 15.6%, Fig. 6D).

Discussion

The present study demonstrates that prolonged +WIN exposure reduces GABAergic synaptic function in cultured hippocampal neurons. Massive neuronal hyperexcitability was observed immediately upon removal of +WIN following a 24-h exposure. Prolonged +WIN exposure resulted in profound downregulation of CB1 receptors, which was accompanied by a modification in GABAergic synaptic transmission as evidenced by decreased mIPSC amplitude and a reduction in number of postsynaptic GABAA receptor channel number. However, there were no changes in number of GABAergic synapses or VGAT positive terminals between −WIN and +WIN-treated cultures. The findings from this study are the first to indicate that chronic exposure of CB1 receptors to agonists can modulate excitability by affecting both changes in presynaptic neurotransmitter release and postsynaptic GABAA receptor channel number.

Miniature inhibitory post synaptic potentials (mIPSPs) are GABAA receptor mediated synaptic events in which each mIPSP represents the release of single quantum of neurotransmitter. The frequency of these events is thought to represent presynaptic release machinery whereas the amplitude is indicative of post-synaptic receptor function (Frerking, et al., 1997). It has been reported that acute applications of CB1 agonists suppress both miniature inhibitory and excitatory post synaptic currents (mIPSC and mEPSC) in hippocampus (Basavarajappa, et al., 2008, Hájos and Freund, 2002, Ohno-Shosaku, et al., 2002). In light of the considerable role of CB1 receptor-dependent modulation of both excitatory and inhibitory neurotransmission, it is important to evaluate how long term cannabinoid use may affect presynaptic CB1 receptor-dependent mechanisms and how the subsequent withdrawal may affect neuronal behavior and synaptic strength.

Our electrophysiological studies showed a 40% reduction in mIPSC amplitude following prolonged +WIN exposure. There are a number of possibilities that could underlie the change in mIPSC amplitude (Barberis, et al., 2004). It could result from a reduction in number of postsynaptic GABAA receptors (Nusser, et al., 1998), or a reduced packaging of GABA into synaptic vesicles (Frerking, et al., 1995, Frerking, et al., 1997), or a change in subunit composition of the receptors that alters single-channel properties (Cherubini and Conti, 2001). Nonstationary fluctuation analysis indicated no significant change in GABAA receptor single-channel conductance, nor were there any major changes in mIPSC kinetics that might indicate differences in subunit composition. These data suggest that GABAA receptor channel properties were not affected following prolonged cannabinoid exposure. However, we did observe a significant reduction in the number of channels open at the peak of the mIPSC. There are limitations to the peak-scaled fluctuation analysis. It cannot determine whether a change in the number of open channels is attributable to a change in channel open probability or a change in GABA concentration in the synaptic cleft, or a reduction in the number of channels clustered at postsynaptic sites (De Koninck and Mody, 1994). Our immunocytochemical and immunoblot analysis of +WIN treated cultures revealed both a reduction in the intensity of staining for surface GABAA2/3 and a significant decrease in total cellular GABAA2/3 subunit expression in parallel with reduced mIPSC amplitude suggesting that the reduction in number of GABAA receptor open channels is, at least in part, due to a reduction in the number of synaptically localized GABAA receptors containing the β2/3 subunit.

The vesicular GABA transporter (VGAT) is a marker for inhibitory terminals. Analysis of double immune staining for VGAT and CB1 in −WIN treated hippocampal cultures revealed a high degree of colocalization which agrees with earlier findings in this preparation (Blair, et al., 2009). We observed no change in the staining intensity of VGAT suggesting that GABA synthesizing infrastructure of inhibitory terminals remained intact following prolonged +WIN treatment. However, it did affect the level of expression of CB1 receptor as demonstrated by an 87% reduction in staining intensity and a loss in CB1 colocalizing with VGAT. Downregulation of the CB1 receptor would result in a loss of its regulatory control over presynaptic GABA release (Ferraro, et al., 2001, Kofalvi, et al., 2005). Prolonged exposure to +WIN resulted in a 2-fold increase in mIPSC frequency compared to −WIN treated cultures, indicating increased GABA release in association with CB1 receptor downregulation.

It has been established that repeated administration of cannabinoids results in development of tolerance to hypothermia, anti-nociception and hypolocomotion (Abood and Martin, 1992). Our previous findings have demonstrated that prolonged exposure to the CB1 agonist +WIN produces tolerance to its anticonvulsant effect in an in vitro preparation of epileptiform activity (Blair, et al., 2009). Studies in humans have shown that cannabis withdrawal following prolonged exposure is prevalent and is characterized by a number of clinically significant symptoms some of which include psychomotor retardation, anxiety, restlessness, irritability, depression, insomnia and in small percentage of abusers, seizures (Hasin, et al., 2008). Recently it was reported that a small subset of multiple sclerosis patients undergoing a long-term oral cannabis treatment regimen to control spasticity, reported seizures while on the drug (Wade, et al., 2006). Additionally, reports have suggested that marijuana use and/or withdrawal could potentially trigger seizures in epileptic patients (Gordon and Devinsky, 2001). Animal studies have shown that after a single exposure to THC, there was enhanced CNS excitability during the withdrawal phase, resulting in increased susceptibility to electrical-induced convulsions (Karler, et al., 1986, Karler and Turkanis, 1980). In agreement with these studies, we observed significant hyperexcitability in our neuronal preparation upon withdrawal of +WIN after a prolonged exposure. However, the precise molecular mechanism underlying this withdrawal related neuronal hyperexcitability is unknown.

Recent studies have shown that the endocannabinoid anandamide is a tonic activator of CB1 receptors on GABAergic terminals in hippocampal slice cultures (Kim and Alger, 2010). Our research has also shown that endocannabinoids block status epilepticus-like activity in cultured hippocampal neurons (Deshpande, et al., 2007). It will be insightful to study the contribution of long-term presence of endocannabinoids (anandamide or 2-AG) by using selective inhibitors of endocannabinoid degradation/reuptake and comparing it to long-term exogenous cannabinoid administration on GABAergic neurotransmission. While it has been shown that CB1 receptors colocalize with both GABAergic and glutamatergic terminals, we have shown that CB1 receptor colocalization on GABAergic terminals predominates over CB1 receptor colocalization on glutamatergic terminals in cultured hippocampal neurons (Blair, et al., 2009). Hence we chose to initially study the GABAergic system in this paper. However, several elegant studies have demonstrated an essential role of CB1-dependent regulation of glutamatergic transmission in models of neuronal hyperexcitability (Monory, et al., 2006, Marsicano, et al., 2003). Thus, future studies to evaluate the effect of agonist-induced downregulation of CB1 on glutamatergic transmission in our model system are warranted.

It has been demonstrated that the presynaptic CB1 receptor functions to regulate synaptic transmission through suppression of neurotransmitter release (Ferraro, et al., 2001, Katona and Freund, 2008, Kofalvi, et al., 2005). We hypothesize that downregulation of CB1 receptors following prolonged agonist exposure as observed in this study and reported earlier (Blair, et al., 2009, Coutts, et al., 2001) would remove this modulatory effect and cause an increased neurotransmitter release (de Fonseca, et al., 1991, Hoffman, et al., 2007), in this case GABA. Increased synaptic availability of GABA would result in a prolonged occupancy of postsynaptic GABAA receptors, which in turn may cause a maladaptive response reflected by decreased receptor density at the cell surface (Alicke and Schwartz-Bloom, 1995, Barnes, 1996, Tehrani and Barnes, 1991). In agreement with this hypothesis, our electrophysiological and immunocytochemical studies show that prolonged +WIN exposure significantly reduced GABAA receptor channel number. Together these effects could underlie the neuronal hyperexcitability immediately following cannabinoid withdrawal observed in this study. Indeed other studies have shown that prolonged neuronal firing following status epilepticus (Blair, et al., 2004, Goodkin, et al., 2005) or extended activity deprivation (Hartman, et al., 2006, Kilman, et al., 2002) in cultured neurons is associated with decreased GABAA receptor number and function. Our study demonstrates a novel role of cannabinoid-dependent presynaptic control of neuronal transmission in that CB1 receptor downregulation following prolonged agonist exposure is associated with a reduction in postsynaptic GABAergic function.

Acknowledgements

We would like to thank Drs. Maurice Elphick and Ken Mackie for the CB1 receptor antibodies. This work was supported by the CounterACT Program, National Institutes of Health Office of the Director, and the National Institute of Neurological Disorders and Stroke (NINDS) [UO1NS058213] to RJD. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the federal government. This study is also supported by NINDS [RO1NS051505 and RO1NS052529] to RJD. Confocal microscopy was performed at the VCU-Dept. of Neurobiology & Anatomy Microscopy Facility, supported, in part, with funding from NIH-NINDS Center core grant [5P30NS047463].

Abbreviations

CB1
Cannabinoid type 1
+WIN/ −WIN
WIN 55212-2/ 3
mIPSC
miniature inhibitory postsynaptic current
VGAT
vesicular GABA transporter

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Reference

1. Abood ME, Martin BR. Neurobiology of marijuana abuse. Trends Pharmacol Sci. 1992;13:201–206. [PubMed]
2. Alicke B, Schwartz-Bloom R. Rapid Down-Regulation of GABAA Receptors in the Gerbil Hippocampus Following Transient Cerebral Ischemia. J Neurochem. 1995;65:2808–2811. [PubMed]
3. Barberis A, Petrini EM, Cherubini E. Presynaptic source of quantal size variability at GABAergic synapses in rat hippocampal neurons in culture. Eur. J Neurosci. 2004;20:1803–1810. [PubMed]
4. Barnes EM., Jr. Use-dependent regulation of GABAA receptors. Int Rev Neurobiol. 1996;39:53–76. [PubMed]
5. Basavarajappa BS, Ninan I, Arancio O. Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons. J Neurochem. 2008;107:1001–1013. [PMC free article] [PubMed]
6. Blair RE, Deshpande LS, Sombati S, Elphick MR, Martin BR, Delorenzo RJ. Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology. 2009;57:208–218. [PMC free article] [PubMed]
7. Blair RE, Deshpande LS, Sombati S, Falenski KW, Martin BR, DeLorenzo RJ. Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus. J Pharmacol Exp Ther. 2006;317:1072–1078. [PubMed]
8. Blair RE, Sombati S, Lawrence DC, McCay BD, DeLorenzo RJ. Epileptogenesis causes acute and chronic increases in GABAA receptor endocytosis that contributes to the induction and maintenance of seizures in the hippocampal culture model of acquired epilepsy. J Pharmacol Exp Ther. 2004;310:871–880. [PubMed]
9. Brünig I, Penschuck S, Berninger B, Benson J, Fritschy JM. BDNF reduces miniature inhibitory postsynaptic currents by rapid downregulation of GABAA receptor surface expression. Eur J Neurosci. 2001;13:1320–1328. [PubMed]
10. Cherubini E, Conti F. Generating diversity at GAB Aergic synapses. Trends Neurosci. 2001;24:155–162. [PubMed]
11. Cohen AS, Lin DD, Coulter DA. Protracted postnatal development of inhibitory synaptic transmission in rat hippocampal area CA1 neurons. J Neurophysiol. 2000;84:2465–2476. [PubMed]
12. Coutts AA, Anavi-Goffer S, Ross RA, MacEwan DJ, Mackie K, Pertwee RG, Irving AJ. Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci. 2001;21:2425–2433. [PubMed]
13. de Fonseca FR, Fernández-Ruiz JJ, Murphy L, Eldridge JC, Steger RW, Bartke A. Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: Evidence of an acute effect and development of tolerance in chronic treatments. Pharmacolo Biochem Behav. 1991;40:593–598. [PubMed]
14. De Koninck Y, Mody I. Noise analysis of miniature IPSCs in adult rat brain slices: properties and modulation of synaptic GABAA receptor channels. J Neurophysiol. 1994;71:1318–1335. [PubMed]
15. Deshpande LS, Blair RE, Ziobro JM, Sombati S, Martin BR, DeLorenzo RJ. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur J Pharmacol. 2007;558:52–59. [PMC free article] [PubMed]
16. Deshpande LS, Sombati S, Blair RE, Carter DS, Martin BR, DeLorenzo RJ. Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy. Neurosci Lett. 2007;411:11–16. [PMC free article] [PubMed]
17. Edwards FA, Konnerth A, Sakmann B. Quantal analysis of inhibitory synaptic transmission in the dentate gyrus of rat hippocampal slices: a patch-clamp study. J Physiol. 1990;430:213–249. [PubMed]
18. Egertová M, Elphick MR. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1. J Comp Neurol. 2000;422:159–171. [PubMed]
19. Ferraro L, Tomasini MC, Cassano T, Bebe BW, Siniscalchi A, O’Connor WT, Magee P, Tanganelli S, Cuomo V, Antonelli T. Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. J Neurosci Res. 2001;66:298–302. [PubMed]
20. Frerking M, Borges S, Wilson M. Variation in GABA mini amplitude is the consequence of variation in transmitter concentration. Neuron. 1995;15:885–895. [PubMed]
21. Frerking M, Borges S, Wilson M. Are Some Minis Multiquantal? J Neurophysiol. 1997;78:1293–1304. [PubMed]
22. Goodkin HP, Yeh J-L, Kapur J. Status Epilepticus Increases the Intracellular Accumulation of GABAA Receptors. J Neurosci. 2005;25:5511–5520. [PMC free article] [PubMed]
23. Gordon E, Devinsky O. Alcohol and Marijuana: Effects on Epilepsy and Use by Patients with Epilepsy. Epilepsia. 2001;42:1266–1272. [PubMed]
24. Hájos N, Freund TF. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology. 2002;43:503–510. [PubMed]
25. Hartman KN, Pal SK, Burrone J, Murthy VN. Activity-dependent regulation of inhibitory synaptic transmission in hippocampal neurons. Nat Neurosci. 2006;9:642–649. [PubMed]
26. Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF. Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry. 2008;69:1354–1363. [PMC free article] [PubMed]
27. Hoffman AF, Oz M, Yang R, Lichtman AH, Lupica CR. Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation. Learn Mem. 2007;14:63–74. [PMC free article] [PubMed]
28. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev. 2002;54:161–202. [PubMed]
29. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M. Endocannabinoid-Mediated Control of Synaptic Transmission. Physiol Rev. 2009;89:309–380. [PubMed]
30. Karler R, Calder LD, Turkanis SA. Prolonged CNS hyperexcitability in mice after a single exposure to delta-9-tetrahydrocannabinol. Neuropharmacology. 1986;25:441–446. [PubMed]
31. Karler R, Turkanis SA. Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice. Br J Pharmacol. 1980;68:479–484. [PubMed]
32. Katona I, Freund TF. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 2008;14:923–930. [PubMed]
33. Kilman V, van Rossum MCW, Turrigiano GG. Activity Deprivation Reduces Miniature IPSC Amplitude by Decreasing the Number of Postsynaptic GABAA Receptors Clustered at Neocortical Synapses. J Neurosci. 2002;22:1328–1337. [PubMed]
34. Kim J, Alger BE. Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat Neurosci. 2010;13:592–600. [PMC free article] [PubMed]
35. Kofalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlagh B. Involvement of Cannabinoid Receptors in the Regulation of Neurotransmitter Release in the Rodent Striatum: A Combined Immunochemical and Pharmacological Analysis. J Neurosci. 2005;25:2874–2884. [PubMed]
36. Mackie K. Cannabinoid receptors as therapeutic targets. Annl Rev Pharmacol Toxicol. 2006;46:101–122. [PubMed]
37. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84–88. [PubMed]
38. Monory K, Massa F, Egertová M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, Long J, Rubenstein JL, Goebbels S, Nave K-A, During M, Klugmann M, Wölfel B, Dodt H-U, Zieglgänsberger W, Wotjak Carsten T., Mackie K, Elphick MR, Marsicano G, Lutz B. The Endocannabinoid System Controls Key Epileptogenic Circuits in the Hippocampus. Neuron. 2006;51:455–466. [PMC free article] [PubMed]
39. Nusser Z, Hajos N, Somogyi P, Mody I. Increased number of synaptic GABA(A) receptors underlies potentiation at hippocampal inhibitory synapses. Nature. 1998;395:172–177. [PubMed]
40. Ohno-Shosaku T, Tsubokawa H, Mizushima I, Yoneda N, Zimmer A, Kano M. Presynaptic Cannabinoid Sensitivity Is a Major Determinant of Depolarization-Induced Retrograde Suppression at Hippocampal Synapses. J Neurosci. 2002;22:3864–3872. [PubMed]
41. Otis TS, De Koninck Y, Mody I. Lasting potentiation of inhibition is associated with an increased number of gamma-aminobutyric acid type A receptors activated during miniature inhibitory postsynaptic currents. Proc Natl Acad Sci U S A. 1994;91:7698–7702. [PubMed]
42. Rajasekaran K, Kapur J, Bertram EH. Alterations in GABAA Receptor Mediated Inhibition in Adjacent Dorsal Midline Thalamic Nuclei in a Rat Model of Chronic Limbic Epilepsy. J Neurophysiol. 2007;98:2501–2508. [PubMed]
43. Tehrani MH, Barnes EM., Jr. Agonist-dependent internalization of gamma-aminobutyric acidA/benzodiazepine receptors in chick cortical neurons. J Neurochem. 1991;57:1307–1312. [PubMed]
44. Traynelis SF, Silver RA, Cull-Candy SG. Estimated conductance of glutamate receptor channels activated during EPSCs at the cerebellar mossy fiber-granule cell synapse. Neuron. 1993;11:279–289. [PubMed]
45. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83:393–411. [PubMed]
46. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Multiple Sclerosis. 2006;12:639–645. [PubMed]
47. Wallace MJ, Blair RE, Falenski KW, Martin BR, DeLorenzo RJ. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J Pharmacol Exp Ther. 2003;307:129–137. [PubMed]
48. Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol. 2002;452:295–301. [PubMed]
49. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol. 2001;428:51–57. [PubMed]
50. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci. 1992;12:1040–1062. [PubMed]